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Objective To investigate recombinant human insulin-like growth factor 1 complexed with its binding protein (rhIGF-
1/rhIGFBP-3) for the prevention of retinopathy of prematurity (ROP) and other complications of prematurity among
extremely preterm infants.
Study design This phase 2 trial was conducted from September 2014 to March 2016. Infants born at a gesta-
tional age of 230/7 weeks to 276/7 weeks were randomly allocated to rhIGF-1/rhIGFBP-3 (250 µg/kg/ 24 hours, con-
tinuous intravenous infusion from <24 hours of birth to postmenstrual age 296/7 weeks) or standard neonatal care,
with follow-up to a postmenstrual age of 404/7 weeks. Target exposure was ≥70% IGF-1 measurements within 28-
109 µg/L and ≥70% intended therapy duration. The primary endpoint was maximum severity of ROP. Secondary
endpoints included time to discharge from neonatal care, bronchopulmonary dysplasia, intraventricular hemor-
rhage, and growth measures.
Results Overall, 61 infants were allocated to rhIGF-1/rhIGFBP-3, 60 to standard care (full analysis set); 24 of 61
treated infants achieved target exposure (evaluable set). rhIGF-1/rhIGFBP-3 did not decrease ROP severity or
ROP occurrence. There was, however, a 53% decrease in severe bronchopulmonary dysplasia in the full analysis
set (21.3% treated vs 44.9% standard care), and an 89% decrease in the evaluable set (4.8% vs 44.9%;
P = .04 and P = .02, respectively) for severity distribution between groups. There was also a nonsignificant trend
toward decrease in grades 3-4 intraventricular hemorrhage in the full analysis set (13.1% vs 23.3%) and in the
evaluable set (8.3% vs 23.3%). Fatal serious adverse events were reported in 19.7% of treated infants (12/61)
and 11.7% of control infants (7/60). No effect was observed on time to discharge from neonatal care/growth
measures.
Conclusions rhIGF-1/rhIGFBP-3 did not affect development of ROP, but decreased the occurrence of severe
bronchopulmonary dysplasia, with a nonsignificant decrease in grades 3-4
intraventricular hemorrhage. (J Pediatr 2018;■■:■■-■■).
Trial registration ClinicalTrials.gov: NCT01096784.
I nsulin-like growth factor-1 (IGF-1) is an important fetal growth regulator, withIGF-1 levels increasing with gestational age, particularly during the second andthird trimesters of pregnancy.1,2 After preterm birth, serum IGF-1 levels de-
crease rapidly and remain low for the first weeks of life relative to corresponding
fetal levels in utero.3,4
Longitudinal studies have reported an association between lower serum IGF-1
levels at birth in extremely preterm infants and an increased risk of retinopathy
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impairment, and growth impairment.5-9 Preclinical models
also support associations between IGF-1 and complications
of prematurity. In mice, IGF-1 absence delays normal retinal
vascular development,10 and recombinant human (rh)IGF-1
administration reduces risk of oxygen-induced retinopathy.11
Additionally, rhIGF-1 administration in a hyperoxia-induced
model of BPD decreases signs of disease in newborn rats.12
Angiogenesis is an important process in both retinal and
lung development,10,13 and it may represent a common un-
derlying mechanism affected by low IGF-1 levels in ROP and
BPD.10,14 In addition, IGF-1 is neuroprotective in rat pups
affected by germinal matrix hemorrhage.15 Together, these
data suggest that ROP, BPD, brain injury/neurodevelopmental
impairment, and growth restriction could be ameliorated by
supplementing postnatal serum IGF-1 to corresponding fetal
levels in extremely preterm infants.
We are investigating the use of rhIGF-1 complexed with its
binding protein rhIGFBP-3 (rhIGF-1/rhIGFBP-3) to prevent
complications of prematurity. Early clinical studies con-
ducted between June 2010 and July 2013 demonstrated fea-
sibility of rhIGF-1/rhIGFPB-3 infusion without safety
concerns.16,17 In the current study, we hypothesized that rhIGF-
1/rhIGFBP-3 administration by continuous intravenous in-
fusion would decrease the severity of ROP and other
complications of prematurity.
Methods
This phase 2, multicenter, randomized, standard of care con-
current control, assessor-masked study evaluated the efficacy
and safety of rhIGF-1/rhIGFBP-3 in decreasing the severity of
ROP and other complications of prematurity (ClinicalTrials.gov:
NCT01096784). The trial was conducted at 20 clinical sites in
Italy, the Netherlands, Poland, Sweden, the United Kingdom,
and the US. Study drug was administered from within 24 hours
after birth until postmenstrual age (PMA) 296/7 weeks, with
follow-up evaluations up to a PMA of 404/7 weeks (Figure 1).
All infants’ parents/guardians provided written informed
consent. The study was reviewed/approved by relevant insti-
tutional review boards/independent ethics committees. Addi-
tional details on safety monitoring and interim analyses are
provided in the Methods section of Appendix 2 (available at
www.jpeds.com). The study adhered to International Confer-
ence on Harmonization Good Clinical Practice guidelines and
the tenets of the Declaration of Helsinki.
Patient Population
Infants with gestational age at birth of 230/7-276/7 weeks were
eligible for enrollment. Exclusion criteria included monozy-
gotic twins, detectable gross malformation, known/suspected
chromosomal abnormality, genetic disorder/syndrome, a per-
sistent blood glucose level of <2.5 mmol/L or >10 mmol/L on
the day of birth, anticipated need for administration of rh eryth-
ropoietin during treatment, a history of maternal diabetes re-
quiring insulin, and clinically significant neurologic disease
(germinal matrix hemorrhage allowed).
Randomization and Masking
Infants were allocated to rhIGF-1/rhIGFBP-3 or standard neo-
natal care (controls) in a 1:1. Dizygotic twins were random-
ized to the same study arm. Randomization was stratified by
gestational age (<26, ≥26 weeks) centrally, using the permuted-
block randomization approach. Investigators were not masked
to treatment assignment, but certain assessments were masked.
ROP stage was evaluated by 2 centralized independent pedi-
atric ophthalmologists (and adjudicated by a third) and cranial
ultrasound scans by a single central examiner.
Treatment Regimen
rhIGF-1/rhIGFBP-3 (mecasermin rinfabate, 50 µg/mL solu-
tion), a 1:1 molar ratio of the noncovalent complex of rhIGF-1
and rhIGFBP-3, was administered via continuous intrave-
nous infusion through a central or peripheral line. Interrup-
tions in the infusion of ≥1 hour were recorded. Standard care
was determined based on the individual preterm infant’s con-
dition following local protocols. The Methods section in
Appendix 2 summarizes information on permitted and pro-
hibited concomitant medications.
Dosing and Target IGF-1 Levels
rhIGF-1/rhIGFBP-3 dosing was standardized to 250 µg/kg/
24 hours with the intention of maintaining serum IGF-1 levels
within 28-109 µg/L, estimated as the normal physiologic in-
trauterine range based on prior literature.18-20 The dose was de-
creased to 125 µg/kg/24 hours if the infant’s serum IGF-1 levels
exceeded the upper bound for 2 consecutively scheduled
samples (plus a confirmatory sample 12 hours after the pre-
vious 2 consecutive samples). The Methods section in
Appendix 2 provides details on sampling intervals andmethods
for IGF-1 measurement.
Outcomes
The primary endpoint was maximum severity of ROP stage
across all retinal examinations, based on retinal camera
(RetCam, Clarity Medical Systems Inc, Pleasanton, Califor-
nia) images of the dilated fundus. ROP assessments were per-
formed every 1-2 weeks between PMA 31 and 40 weeks. ROP
was classified according to the International Classification.21
For treatment, the recommendations of the Early Treatment
for Retinopathy of Prematurity Cooperative Group were
followed.22 The International Classification is based on an
ordinal scale with higher numbers indicating a more severe
outcome: 0, 1, 2, 3, 3+, 4, and 5.
A prespecified key secondary endpoint was time between
day of birth and day of discharge from neonatal care. Other
secondary outcome measures included incidence of BPD and
intraventricular hemorrhage (IVH) and assessment of growth
(weight, length, and head circumference). BPD was assessed
by need for oxygen use during the first 28 days after birth and
by oxygen challenge testing at PMA of 363/7 weeks.23,24 Defi-
nitions of mild, moderate, and severe BPD were based on the
National Institute of Child Health and Human Development
criteria for preterm infants born before 32 weeks of gestation.23
The presence of cerebral hemorrhage was assessed by cranial
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ultrasound scanning before study inclusion, at postnatal days
3, 7, 14, and 21 (±1 day), and at PMA 40 weeks (±4 days), and
graded between 0 and 4 using the Papile/Bowerman scoring
method.25,26 Ultrasound images were graded by a single reader
masked to study group. Brain volumetric measurements were
performed on magnetic resonance images obtained at PMA
40 weeks and will be reported separately.
Safety Assessments
Adverse events (AEs) and serious AEs (SAEs) were recorded
from receipt of informed consent until final study examination/
sampling at PMA 40 weeks. Investigator Verbatim Terms de-
scribing AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA; version 16.0) to MedDRA Pre-
ferred Terms (Table I [available at www.jpeds.com] for
Randomized/assigned
to treatment (n = 121)
Allocated to standard neonatal care (n = 60)
  • Received allocated intervention (n = 60)
Allocated to rhIGF-1/rhIGFBP-3 (n = 61)
  • Received allocated intervention (n = 61)
Analyzed (n = 61)
  • Completed (n = 46)
Safety analysis population (n = 61)
Intention-to-treat population (n = 61)
FAS (n = 61)
ES (n = 24)
Analyzed (n = 60)
  • Completed (n = 46)
Safety analysis population (n = 60)
Intention-to-treat population (n = 60)
FAS (n = 60)
Discontinued intervention (n = 15) 
  • Consent withdrawn (n = 2)†
  • AE (n = 11)‡
  • Protocol deviation (n = 2)
  • Administrative decision (n = 0)
  • Other (n = 0)
Discontinued intervention (n = 14)
  • Consent withdrawn (n = 1)
  • AE (n = 9)§
  • Protocol deviation (n = 2)
  • Administrative decision (n = 1)




(within 24 hours of birth) 
rhIGF-1/rhIGFBP-3
250 µg/kg/24 hours
Continuous IV infusion   
Day of birth,









Figure 1. A, Study design and B, patient disposition. *Informed consent was obtained before birth or within 24 hours after birth.
† One infant had an SAE with a fatal outcome, but the primary reason for discontinuation was withdrawal of consent. ‡ All infants
discontinued owing to an SAE with fatal outcome. § Seven of 9 discontinuations were owing to SAEs with fatal outcome.
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reported Verbatim Terms for commonly observed AEs). The
Methods section in Appendix 2 describes other definitions and
assessments of AEs.
Statistical Analyses
A sample size of 40 infants per treatment group (80 total) was
estimated to provide 80% power (significance level, 5%) to
demonstrate a statistically significant difference in distribu-
tion of ROPmaximum severity between groups (primary end-
point). The ROP outcome stages in the current study were
classified as 0, 1, 2, 3, and >3, which is the expected possible
range of ROP stages that would be encountered in the study,
based on analysis of Swedish infants screened for ROP from
2004 to 2008. Based on Swedish registry data,27 the propor-
tion of children with each ROP outcome for the control group
is provided in Table II (available at www.jpeds.com). An es-
timated treatment effect among treated infants is also pre-
sented. The estimated treatment effect was calculated based on
the following assumptions: For each outcome of the maximum
severity of ROP stage, it is assumed that 25% of the children
will not benefit from the treatment, 25% will have their
maximum severity of ROP stage reduced by 1 level (eg, from
2 to 1), and 50% will have their maximum severity of ROP
stage reduced 2 levels (eg, from 3+ to 2). The null hypothesis
tested whether the distribution of maximum severity of ROP
stage across all retinal examinations was the same for both treat-
ment groups. Assuming a 30% nonevaluable/dropout rate, 120
infants (60 per group) were to be randomly assigned. The study
was powered for the primary ROP endpoint only. A sample
size of 80 evaluable infants was also estimated to provide ad-
equate power for the key secondary endpoint (time to dis-
charge from neonatal intensive care), but no power calculations
were performed for BPD or IVH secondary endpoints. The
Methods section in Appendix 2 provides additional details on
the statistical evaluation of all endpoints.
The intention-to-treat population included all enrolled
infants assigned a randomization number. The full analysis set
(FAS) was defined as all randomized infants receiving study
drug or standard care. For rhIGF-1/rhIGFBP-3–treated infants,
the FAS was the same as the intention-to-treat population
because all randomized infants started treatment. The evaluable
set (ES) included treated infants in the FAS who had ≥70%
of serum IGF-1 levels within the target range (28-109 µg/L)
and who received ≥70% of the intended duration of infusion
of rhIGF-1/rhIGFBP-3 (overall infusion length excluding in-
terruptions of ≥1 hour). For the standard care group, the FAS
was also considered to be the ES. The safety population in-
cluded randomized infants receiving study drug or standard
care for whom ≥1 safety assessment was completed. The phar-
macokinetic population included infants receiving study drug
who had ≥1 blood samples drawn after administration.
Results
The first infant was enrolled September 19, 2014, and the last
infant completed March 30, 2016. Overall, 121 infants were en-
rolled, of whom 29 did not complete the study (19 of 29 owing
to death; Figure 1). Sixty-one infants received rhIGF-1/
rhIGFBP-3 and 60 standard of care. Thirty-five of 61 treated
infants (57.4%) and 32 of 60 control infants (53.3%) were born
before 26 weeks gestational age (Table III).Mean average daily
dose of rhIGF-1/rhIGFBP-3 was 248.1 µg/kg/24 hours (range,
131.1-250.0 µg/kg/24 hours); the total duration of exposure
was 23.8 days (range, 0.1-45.3 days); the ratio of duration of
exposure to expected duration (birth to 296/7 weeks PMA) was
0.86 (range, 0.0-1.0); and the number of infusion interrup-
tions of ≥1 hour was 4.0 per treated infant (range, 0-83 per
treated infant). Table IV (available at www.jpeds.com)
provides details on exposure by gestational age strata. Among
treated infants, 52 of 61 received ≥70% of the expected treat-
ment duration and 28 of 61 had ≥70% of IGF-1 levels within
the target range. Overall target exposure (based on duration
and IGF-1 level) was achieved for 24 of 61 treated infants (ES).
The Results section in Appendix 2 and Figure 2 (available at
www.jpeds.com) summarize information on attained serum
IGF-1 levels.
Primary Endpoint: ROP
Considering the FAS, 25.5% of rhIGF-1/rhIGFBP-3–treated
infants developed ROP stage ≥3 vs 18.0% of controls; there















Male 39 (65.0) 39 (63.9) 14 (58.3)
Female 21 (35.0) 22 (36.1) 10 (41.7)
Gestational age group, no. (%)
<26 wk 32 (53.3) 35 (57.4) 10 (41.7)
≥26 wk 28 (46.7) 26 (42.6) 14 (58.3)
Gestational age
Mean, wk 254/7 254/7 257/7
±SD, d ±10 ±8 ±9
SGA, no. (%) 10 (16.7) 11 (18.0) NA
Weight at birth
Mean, kg 0.804 0.780 0.847
SD, kg 0.174 0.183 0.192
Race, no. (%)
Asian 5 (8.3) 4 (6.6) 1 (4.2)
Black or African American 9 (15.0) 5 (8.2) 3 (12.5)
White 42 (70.0) 49 (80.3) 19 (79.2)
Other 4 (6.6) 3 (4.9) 1 (4.2)
Mode of delivery, no. (%)
Vaginal 27 (45.0) 25 (41.0) 10 (41.7)
Cesarean 33 (55.0) 36 (59.0) 14 (58.3)
Maternal infections, no. (%) 14 (23.3) 11 (18.0) 3 (12.5)
Clinical chorioamnionitis, no. (%) 6 (10.0) 10 (16.4) 2 (8.3)
Maternal antibiotics, no. (%) 38 (63.3) 32 (52.5) 12 (50.0)
Antenatal steroids, no. (%) 60 (100.0) 61 (100.0) 24 (100.0)
Fertility therapy, no. (%) 9 (15.0) 10 (16.4) 2 (8.3)
IVF 7 (11.7) 10 (16.4) 2 (8.3)
Ovulation stimulation 2 (3.3) 0 0
Preterm labor, no. (%) 53 (88.3) 50 (82.0) 19 (79.2)
Preterm premature rupture
of membranes, no. (%)
20 (33.3) 18 (29.5) 8 (33.3)
Preeclampsia, no. (%) 5 (8.3) 7 (11.5) 2 (8.3)
IVF, in vitro fertilization; NA, not available; SGA, small for gestational age.
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was no statistically significant difference between the 2 groups
in distribution of maximum severity of ROP (P = .06; Table V).
In the ES, similar proportions of treated vs control infants had
ROP of stage ≥3 (18.2% vs 18.0%, respectively; P = .24 for
severity distribution between groups). A breakdown by
gestational age strata for ROP/other endpoints is presented
in Table VI, Table VII, and Table VIII (available at
www.jpeds.com). The number of infants who received treat-
ment for ROP was similar between treatment groups: stan-
dard of care, 7 (all laser therapy); rhIGF-1/rhIGFBP-3, 7 (6 laser
therapy, 1 anti-vascular endothelial growth factor only).
Post hoc analysis of IGF-1 levels by ROP severity (<3, ≥3)
across weeks after birth showed a clear separation for mean
IGF-1 profiles between treated and control infants; in the rhIGF-
1/rhIGFBP-3 group, an association of higher serum IGF-1 with
less severe ROP was observed (Figure 3, A).
Key Secondary Endpoint: Time to Discharge From
Neonatal Care
In the overall population (FAS), the median time to dis-
charge was 82 days (range, 55-115 days) in the rhIGF-1/
rhIGFBP-3 group and 74 days (range, 51-107 days) among
controls. The difference between groups was not statistically
significant (P = .37). In the ES, median time to discharge was
74 days in both study arms (P = .43).
Secondary Endpoints
A statistically significant difference in distribution of BPD
severity was observed between groups (FAS, P = .04; ES,
P = .02; Table V), with an apparent shift toward milder BPD
cases with treatment. In the FAS, 21.3% of infants with BPD
assessments (10/47) in the rhIGF-1/rhIGFBP-3 group had
severe BPD vs 44.9% of controls (22/49). The difference
between treatment groups was more pronounced in the ES,
with 4.8% of treated infants (1/21) with severe BPD vs
44.9% of controls.
The BPD analyses did not include the 19 all-cause deaths
that occurred in the study, including 12 deaths (20%) in the
rhIGF-1/rhIGFBP-3 group and 7 deaths (12%) in the stan-
dard care group.We conducted post hoc analyses for BPD that
included all-cause deaths during the study period. In the ad-
ditional analyses, deaths were grouped with severe BPD. These
analyses showed that, when deaths were included, the trend
for a decrease in severe BPD among treated infants remained
(37.3% in rhIGF-1/rhIGFBP-3 group vs 51.8% in the stan-
dard of care group Table IX [available at www.jpeds.com]).
In this study, we observed a shift in the distribution of se-
verity of BPD,which wasmost evident in the difference between
groups in the percentage of subjects with severe BPD. If mod-
erate cases were combined with severe cases and deaths, 52.5%
of the rhIGF-1/rhIGFBP-3 group (31/59) and 60.7% of the stan-
dard care group (34/56) had BPD.When early deaths (within
the first 14 days) were excluded, as suggested by Higgins et al
in the 2016 National Institute of Child Health and Human De-
velopment [NICHD] workshop,28 31.5% of the rhIGF-1/
rhIGFBP-3 group (17/54) vs 50.0% of the standard of care
group (27/54) had severe BPD.
Post hoc analysis of IGF-1 levels by BPD severity (mild,mod-
erate, severe) across weeks after birth showed a clear separa-
tion for mean IGF-1 profiles between treated and control
infants, with a higher serum IGF-1 associated with less severe
BPD in the treated group (Figure 3, B).
A smaller proportion of infants in the rhIGF-1/rhIGFBP-3
group had severe IVH (grades 3-4) than among controls
(Table V): FAS, 13.1% vs 23.3%, respectively; ES, 8.3% vs 23.3%,
respectively (not statistically significant). The numbers of IVH
events were too small to explore an exposure-response rela-
tionship between IGF-1 levels and IVH grade.
rhIGF-1/rhIGFBP-3 treatment did not affect rates of change
of length, weight, or head circumference compared with stan-
dard of care (Figure 4 [available at www.jpeds.com]). Similar
results were seen in both the FAS and ES.
Safety
All infants had ≥1 treatment-emergent AEs, with the excep-
tion of 1 infant in the rhIGF-1/rhIGFBP-3 group. For 13.1%
of treated infants (8/61), treatment-emergent AEs were con-
sidered possibly related to study drug. Themost common events
overall (related or unrelated) were patent ductus arteriosus
Table V. Maximum severity of ROP stage, severity of





FAS (n = 61) ES (n = 24)
ROP
Infants with ROP examination, no. 50 47 22
Infants with maximum severity
of ROP of stage, no. (%)
0 24 (48.0) 14 (29.8) 8 (36.4)
1 4 (8.0) 4 (8.5) 2 (9.1)
2 13 (26.0) 17 (36.2) 8 (36.4)
3 3 (6.0) 6 (12.8) 2 (9.1)
3+ 6 (12.0) 6 (12.8) 2 (9.1)
4 0 0 0
5 0 0 0
≥3 9 (18.0) 12 (25.5) 4 (18.2)
Missing, no.* 10 14 2
P value† .06 .24
BPD
Infants with BPD assessment, no. 49 47 21
Severity of BPD, no. (%)
No BPD 4 (8.2) 4 (8.5) 2 (9.5)
Mild 16 (32.7) 23 (48.9) 13 (61.9)
Moderate 5 (10.2) 9 (19.1) 5 (23.8)
Severe 22 (44.9) 10 (21.3) 1 (4.8)
Unable to determine 2 (4.1) 1 (2.1) 0
P value† .04‡ .02‡
IVH
IVH grade, no. (%)
0-1 42 (70.0) 49 (80.3) 20 (83.3)
2 4 (6.7) 4 (6.6) 2 (8.3)
3 9 (15.0) 6 (9.8) 2 (8.3)
4 5 (8.3) 2 (3.3) 0
P value† .14 .18
*The majority (11/12 treated [FAS] and 5/7 control infants) of infants who died in this study
had died before the first scheduled ROP assessment at week 31. Other reasons for not being
evaluated included withdrawal of consent and difficulties in capturing quality RetCam images.
†Cochran–Mantel–Haenszel row mean score test.
‡Difference in the distribution of BPD severity seen between the rhIGF-1/rhIGFBP-3 (FAS or ES)
and standard care groups is statistically significant.
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(90.2% of treated infants vs 85.0% of controls) and neonatal
anemia (75.4% vs 73.3%, respectively; Table X; available at
www.jpeds.com). Additionally, 78.7% of treated infants (48/
61) and 61.7% of control infants (37/60) had SAEs.
Fatal SAEs were reported in 19.7% of treated infants (12/
61) and 11.7% of control infants (7/60); none were consid-
ered treatment related (Table XI). The imbalance of deaths was
concentrated in the subgroup born at a gestational age of <26
weeks and driven by 1 iatrogenic death owing to a misplaced
umbilical catheter (which caused intra-abdominal hemor-
rhage leading to multiorgan failure), 1 infant with severe re-
spiratory distress with onset before study drug infusion, and
3 more cases of necrotizing enterocolitis (NEC). Overall, NEC
AEs (fatal and nonfatal) were balanced between groups (6
infants [9.8%] in the treated group vs 5 infants [8.3%] in the
standard care group). Further explorations revealed no ap-
parent differences in modes of delivery, transfusions, sepsis
events, antibiotic/probiotic use, or nutrition between infants
with NEC who died and those who survived. In addition to
NEC (which can be misclassified as a bowel perforation), 1
infant who died in the rhIGF-1/rhIGFBP-3 group had an in-
testinal perforation and 2 infants who died in the standard care
group had intestinal perforations. Overall, including nonfa-
tal cases, there was 1 case of intestinal perforation in the rhIGF-
1/rhIGFBP-3 group, compared with 5 in the standard of care









rhIGF-1/rhIGFBP-3 and ROP severity of <3 rhIGF-1/rhIGFBP-3 and ROP severity of ≥3
Standard neonatal care and ROP severity of <3 Standard neonatal care and ROP severity of ≥3





























rhIGF-1/rhIGFBP-3 and mild/moderate BPD rhIGF-1/rhIGFBP-3 and severe BPD
Standard neonatal care and mild/moderate BPD Standard neonatal care and severe BPD



















Figure 3. IGF-1 levels by A, ROP severity* and B, BPD severity† by postnatal week. *Mean (±SE) serum IGF-1 levels and
ROP severity (<3, ≥3) in the rhIGF-1/rhIGFBP-3 and standard neonatal care groups by postnatal week. †Mean (±SE) serum
IGF-1 levels and BPD severity (mild, moderate, or severe) in the rhIGF-1/rhIGFBP-3 and standard neonatal care groups by
postnatal week. Note: If an infant had multiple IGF-1 levels in a day, then IGF-1 level was averaged for the day.
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and AEs of interest is provided in the Results section in
Appendix 2.
Discussion
This study did not meet the primary endpoint of reducing
maximum severity of ROP. However, there was a marked de-
crease in the proportion of rhIGF-1/rhIGFBP-3–treated infants
who developed severe BPD, and a shift in patterns of BPD se-
verity to milder cases; a similar trend was observed for IVH
but was not statistically significant. rhIGF-1/rhIGFBP-3 was
well-tolerated in this study; there were no safety signals. The
overall results of this study support continued evaluation of
rhIGF-1/rhIGFBP-3 for the prevention of complications of pre-
maturity in extremely preterm infants.
Although a trend toward higher serum IGF-1 in rhIGF-1/
rhIGFBP-3–treated infants with no or lower stages of ROP was
observed, the reason for lack of overall effect on ROP is not
clear. It may be that the dosing regimen of rhIGF-1/rhIGFBP-3
requires further optimization. Alternatively, practice variabil-
ity in RetCam assessments may have limited the observed treat-
ment effect. A further consideration is the variation between
sites in target oxygen saturation measures and compliance with
these levels. This consideration is particularly important in light
of findings from 5 landmark clinical trials, published shortly
before commencement of the current study, which studied the
effects of targeting lower (85%-89%) vs higher (91%-95%)
oxygen saturation targets on neurodevelopmental impair-
ment and severe ROP in extremely preterm infants.29-31 The
US Surfactant, Positive Pressure, and Oxygenation Random-
ized Trial (SUPPORT) associated a lower oxygenation target
of 85%-90%, as compared with a higher target of 91%-95%,
with increasedmortality and decreased ROP among survivors.29
Combined findings from the Benefits of Oxygen Saturation
Targeting II (BOOST II) trials,30 conducted in the UK, Aus-
tralia, and New Zealand, were largely consistent with the
SUPPORT study. The investigators reported increased mor-
tality in the lower oxygen target group vs the higher (among
infants with revised oximeter software) and a lower rate of
severe ROP in the lower saturation range vs the higher (among
infants in the total study population).30 Conversely, the Ca-
nadian Oxygen Trial (COT) found no significant difference in
mortality or the incidence of severe ROP between the lower
and higher oxygen target groups.31 Findings from the SUPPORT
and BOOST II trials led to changes in neonatal clinical prac-
tice, where the risk of ROP needed to be considered against
the risk of increased mortality, with the result that many centers
across countries adopted higher oxygen target ranges. More
recent studies have reported increased rates and severity of ROP
among extremely preterm infants after changing from lower
to higher oxygen target ranges.32,33 It is possible that higher
oxygen target ranges used in centers in the current study may
have affected the observed incidences of ROP in the study
population.
The key secondary endpoint of time to discharge from neo-
natal care also was not statistically different between groups.
However, it is difficult to draw conclusions from these data
because assessment of length of stay in intensive care is easily
confounded. There also was a lack of effect of rhIGF-1/
rhIGFBP-3 on growth measures, which could have been con-
founded by nutritional differences across sites; unfortunately,
nutrition data were not recorded consistently, precluding further
analysis of a potential effect.
By contrast, the shift in severity distribution of BPD was
marked and suggests a hypothesis-generating trend with higher
serum IGF-1. The rate of IVH events was too low to evaluate
correlations with IGF-1 levels, but a similar trend toward a de-
crease in grades 3-4 IVH in the ES vs the FAS was observed.
Although it remains unclear why such a marked effect was seen
Table XI. Fatal treatment-emergent SAEs (preferred terms)
Standard care rhIGF-1/rhIGFBP-3
Gestational age <26 wk Gestational age ≥26 wk Gestational age <26 wk Gestational age ≥26 wk












>7 and ≤14 0 0 0 0



















*Early-onset sepsis owing to Escherichia coli.
†Verbatim Terms under the Preferred Term “renal failure neonatal” were “renal insufficiency” and “acute renal failure.”
‡Catheter-related sepsis owing to Staphylococcus epidermidis.
§Sepsis owing to Enterococcus faecalis, Staphylococcus aureus, and Staphylococcus haemolyticus.
¶Verbatim terms under the preferred term “neonatal respiratory failure” were “respiratory insufficiency” and “respiratory failure.”
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for BPD relative to ROP, these observations support the hy-
pothesis that increasing serum IGF-1 levels can decrease the
severity of complications of prematurity.
An analysis of the achieved serum IGF-1 levels indicates that
attainment of target levels could be further optimized to po-
tentially improve outcomes.An interim pharmacokinetic analy-
sis in the first 10 treated infants supported the appropriateness
of the 250 µg/kg/24 hours dose to achieve IGF-1 target levels.20
However, in the treated population, although the proportion
of IGF-1 measurements within target was substantially greater
than among controls, fewer than one-half of infants (28/61
[45.9%]) achieved ≥70% of IGF-1 measurements within the
target range (see the Results section in Appendix 2). It is
possible that the slightly lower than anticipated target attain-
ment could relate to technical aspects of drug administra-
tion or that intercurrent proinflammatory states could have
led to fluctuations in IGF-1 levels.34 Alternatively, these ob-
servations may point to a need for further dose optimization.
The observed safety profile of rhIGF-1/rhIGFBP-3 was en-
couraging. There was an imbalance in deaths between the treat-
ment arms concentrated in the subgroup with a gestational age
of <26 weeks; however, careful evaluation of the causes of death
by an independent data monitoring committee did not raise
safety concerns (see the Results section in Appendix 2).With
regard to other safety considerations, despite the duration of
intravenous infusion, data collected to date across rhIGF-1/
rhIGFBP-3 clinical trials have shown no signs of an increase
in pathogen-confirmed sepsis. Also in the current study, the
proportion of infants with hypoglycemia was similar between
groups. Of note, rhIGF-1/rhIGFBP-3 was associated with a
lower incidence of hyperglycemia relative to standard care, sug-
gesting possible improvements in glycemic control. A previ-
ous phase of the study (B/C) found that rhIGF-1/rhIGFBP-3
was well-tolerated in extremely preterm infants and that the
incidence of AEs was similar for infants treated with rhIGF-
1/rhIGFBP-3 vs control infants.35 Further, consistent with the
current trial, rates of hypoglycemia were similar between groups
in the phase B/C study. These outcomes will be of interest for
further investigation.
The limitations of this study included the smaller than an-
ticipated number of infants eligible for inclusion in the ES, albeit
an arbitrary a priori definition.Another limitation was the ran-
domization by gestational age centrally and not by study site,
which resulted in an imbalance between gestational age strata
at high enrolling sites, and may have been an additional con-
founder. Additionally, there were technical challenges to per-
forming certain assessments (eg, RetCam) and variability of
practices across and within sites. The analysis of AEs was limited
by some reporting inconsistency, largely owing to a lack of in-
ternational consensus on defining and classifying AEs in infants
based on their severity. A further consideration is that infants
who died were not included in the analyses, and this factor may
have had an impact on our findings related to the degree of
difference in severe BPD between the 2 groups. However, post
hoc analyses showed similar, although attenuated, results when
all-cause death was included with severe BPD as an outcome.
Although the prevalence of ROP, BPD, and IVHwas comparable
with the observed prevalence in the extremely preterm
population,36,37 the sample size was relatively small. The latter
limitation obviously precludes the evaluation of a possible con-
founding effect of mortality on differences in respiratory mor-
bidity between study groups at a gestational age of 36 weeks.
A larger investigation that examines a higher dose IGF-I with
more standardized and harmonized approaches to safety as-
sessments is needed to clarify this issue, including the evalu-
ation of treatment effects on NEC. Preclinical models indicate
that IGF-I supplementation and subsequent enhancement of
vascular endothelial growth factor receptor-2 signalingmay have
a preventive effect on development of NEC.38-42 Higher levels
of plasma IGF-1 were also associated with reduced incidence
of NEC in a prospective analysis of very low birth weight infants
in the NIRTURE study.43 The administration of IGF-1/
IGFBP3 would not be expected to increase the risk of NEC.
Of note, there were additional protocol limitations associ-
ated with the methodology used to assess presence of IVH (a
single reader of cranial ultrasound examinations, grading only
by the Papile/Bowerman method25,26), which may have im-
pacted the frequency of the various grades seen in both treat-
ment groups. Post hoc analyses are ongoing using an
adjudicated reader and 2 additional scoring methods44,45 for
the assessment of ultrasound scans to evaluate whether the fre-
quency of the various grades varied as a function of the scoring
method; details of the comparison (also including magnetic
resonance imaging data) will be reported separately.
Based on the results of this study and given the clear unmet
need for therapies to decrease the overall morbidity burden
in extremely preterm infants,46-49 continued investigation of
rhIGF-1/rhIGFBP-3 for the prevention of complications of pre-
maturity is planned in a larger clinical trial. The protocol for
this study is in development, with the prevention of the onset
of chronic lung disease (indicated by reductions in respira-
tory complications) at a corrected age of 12 months as the
primary endpoint, and a decrease in the severity of BPD at a
PMA of 36 weeks and IVH severity at a PMA of 40 weeks as
separate key secondary endpoints. Of importance, long-term
outcomes after short-term exposure to rhIGF-1/rhIGFBP-3 also
are being investigated in an extension study (PEDAL;
NCT02386839) over 5 years. ■
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Appendix 1




SafetyMonitoring. A clinical studymonitor ensured that the
investigation was conducted according to protocol design and
regulatory requirements through frequent site visits and com-
munications. Infant safetywasmonitored on a continuous basis
until the last infant completed the last scheduled study visit/
assessment, and quarterly safety review meetings were held
throughout the study. Safety data collected during the trial were
reported annually to competent authorities in the form of a
Development Safety Update Report. Additionally, an inde-
pendentdatamonitoring committeeprovided anongoing review
and assessment of safety data.A special datamonitoring com-
mittee meeting was to be convened if the safety-related stop-
ping rules (ie, if a death occurred that was considered possibly
or probably related to the study drug) were met.
InterimAnalyses. Two interim analyses were planned and con-
ducted. The first was an analysis of dosing/target attainment
conducted when 10 treated infants had completed the rhIGF-
1/IGFBP-3 dosing phase of the study (reported previously by
Chung et al1). In the second, a conditional power analysis was
performed on unmasked data when 60 infants had com-
pleted the study or withdrew early. The analysis was per-
formed by an external independent statistician to assess the
appropriateness of the sample size and assumptions made re-
garding the distribution of the maximum severity of
ROP.
Concomitant Medications. Predefined medications (includ-
ing hydrocortisone, betamethasone, dexamethasone, ibupro-
fen, dopamine, dobutamine, epinephrine, budesonide,
furosemide, nitric oxide, Curosurf/other surfactants, indo-
methacin, and other medications given to treat AEs) and
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procedures administered to infants from time of informed
consent through to a PMA of 404/7 weeks were regarded as per-
mitted. Treatment with fresh frozen plasma, which is associ-
ated with a short-term increase of serum concentrations of
IGF-1,2 was permitted and recorded. Anti-vascular endothe-
lial growth factor medication and rh erythropoietin were pro-
hibited. Delivery of parenteral/enteral nutrition (including
glucose) was performed according to local guidelines.
IGF-1 Blood Sampling. Blood samples for IGF-1 measure-
ment were obtained at baseline (predose), 12 hours ± 30
minutes, and 24 hours ± 30 minutes after the infusion started,
then every 72 ± 1 hours until a PMA of 296/7 weeks, and then
1 hour ± 30 minutes after the infusion stopped for treated
infants. Controls were tested at baseline (day of birth), 12
hours ± 30 minutes, 24 hours ± 30 minutes, and then every 168
± 1 hours after baseline until a PMA of 296/7 weeks. Addi-
tional sampling occurred at PMA 32, 36, and 40 weeks. IGF-1
was determined locally by a validated ELISA (Mediagnost
GmbH, Reutlingen, Germany), and in a central laboratory by
radioimmunoassay (PPD Laboratories, Richmond,Virginia).3
SafetyAssessments. Hypoglycemia was defined within the trial
as plasma glucose levels of <2.5 mmol/L measured during pre-
defined schedules of blood glucose monitoring (see Blood
Glucose Monitoring section), and from blood glucose mea-
surements performed on clinical indication. Hyperglycemia
was defined as plasma glucose levels of >10 mmol/L.
Echocardiography was interpreted by a pediatric cardiologist
to define presence of clinically significant patent ductus arte-
riosus on postnatal days 2 and 4, and according to clinical judg-
ment after these time points. All infants were assessed for
tonsillar hypertrophy by visual examination of their tonsils
during a weekly physical examination and at term age (PMA
of 40 weeks) by a pediatric specialist.
Blood Glucose Monitoring.
rhIGF-1/rhIGFBP-3 Group. For infants who were fed every
2 hours or who were fed intravenously or through continu-
ous enteral feed, blood glucose measurement was performed
every 4 hours during the first 72 hours (days 1-3) after start-
ing infusion with rhIGF-1/rhIGFBP-3. For infants who were
fed every 3 hours, blood glucose was measured every 3 hours
during the first 72 hours (days 1-3) after starting infusion with
rhIGF-1/rhIGFBP-3. During days 4-7, blood glucose was mea-
sured every 6 hours for those infants who were fed either every
2 or every 3 hours. After the first 7 days of the infusion, blood
glucose was analyzed twice daily until the completion of in-
fusion (PMA of 296/7 weeks). Thereafter, blood glucose wasmea-
sured weekly until the end of the study. If blood glucose was
<3 mmol/L during ongoing rhIGF-1/rhIGFBP-3 infusion and
more frequent monitoring was deemed necessary based on the
clinical judgment of the investigator, a blood glucose sample
was then taken every hour until a blood glucose of ≥3 mmol/L
was reached. Clinical sites had specific protocols in place to
monitor hypoglycemia.
Standard Neonatal Care Group. Blood glucose was ana-
lyzed every 6 hours for the first 7 days. Thereafter, it was ana-
lyzed twice daily until a PMA of 296/7 weeks, provided that blood
was available for sampling. If blood was not available, the sample
collection interval was increased. After PMA 296/7 weeks, blood
glucose was measured weekly until the end of the study.
Statistical Analyses. The primary endpoint between the 2
groups was analyzed using a generalized Cochran–Mantel–
Haenszel row means score statistic with modified ridit scores
adjusting for gestational age strata. This statistical test gener-
ates an estimate of an association between an exposure and
an outcome after adjusting for or taking into account con-
founding factors. The sample size of 80 evaluable infants also
was to provide adequate power for the key secondary end-
point of time to discharge from neonatal care, for which the
difference between the 2 treatment groups was tested using the
stratified version of the Wilcoxon rank-sum test and ad-
justed for gestational age status. In the event of death, time to
discharge was imputed using the median value of all infants
with available data within each gestational age strata. The com-
parison between treatment groups for ordered category of BPD
(absent, mild, moderate, severe) at PMA 36 weeks was made
using Cochran–Mantel–Haenszel rowmean score statistics with
modified ridit scores adjusting for gestational age strata. The
grade of the hemorrhage (grades 1-4) was summarized de-
scriptively by treatment group and gestational age strata. The
difference in the distribution of IVH severity seen between the
rhIGF-1/rhIGFBP-3 (FAS or ES) and standard care groups was
analyzed in a post hoc analysis using Cochran–Mantel–
Haenszel row mean score statistics. Weight, length, and head
circumference were analyzed separately, using a linear mixed-
model repeated measurement analysis over all postbaseline
visits, with change from baseline in each parameter as the
outcome variable. The model included treatment time (days),
treatment by time interaction, gestational age strata as a fixed
effect, infant as a random effect, and baseline value as covariate.
Time (days) was calculated relative to the date of the base-
line assessment and was used as a continuous covariate.
Results
Serum IGF-1 Levels. For rhIGF-1/rhIGFBP-3–treated infants,
66.2% of IGF-1 measurements were within the targeted physi-
ological intrauterine range (28-109 µg/L) vs 6.3% for the stan-
dard care group (predose data and data after the end of the
final infusion were excluded). Very few IGF-1 measurements
(1.5%) in treated infants were above the upper bound of the
targeted range. Figure 2 shows the mean (SD) serum IGF-1
concentrations over the duration of the study in both the
rhIGF-1/rhIGFBP-3 and standard care groups; mean concen-
trations were within target range during the infusion period
for treated infants and below range for the standard care group.
The onset of endogenous IGF-1 production was estimated
between weeks 30 and 32 (corresponding approximately with
cessation of treatment), after which both groups had mean
IGF-1 levels within the target range.
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Additional Safety Results.
Severe AEs. In the rhIGF-1/rhIGFBP-3 vs standard care groups,
73.8% of infants (45/61) vs 65.0% of infants (39/60) experi-
enced SAEs, respectively. Only 1 treated infant (1.6%) had 2
SAEs considered possibly related to study drug (1 AE of IVH
and 1 separate AE of apnea).
Discontinuations Owing to AEs. A total of 20 infants (11
[18%] in the rhIGF-1/rhIGFBP-3 group and 9 [15%] in the
standard care group) discontinued the study owing to
treatment-emergent AEs, which were fatal SAEs in 90% of
infants (18/20). One additional infant in the treated group had
an SAE with fatal outcome, but the primary reason for dis-
continuation was withdrawal of consent.
AEs of Interest. The frequency of pathogen-confirmed sepsis
was similar between the rhIGF-1/rhIGFBP-3 and standard care
groups (65.9% vs 67.4%, respectively). Coagulase-negative
staphylococcal sepsis was reported in similar percentages of
infants in each group: 36.4% vs 37.2% in the rhIGF-1/
rhIGFBP-3 and standard care groups, respectively. Hypogly-
cemia occurred in a similar proportion in each group: 29.5%
of infants (18/61) in the rhIGF-1/rhIGFBP-3 group had AEs
of hypoglycemia (considered possibly related to treatment for
4 infants) vs 31.7% (19/60) in the standard care group. Ad-
ditionally, 39.3% of infants (24/61) in the rhIGF-1/rhIGFBP-3
group had AEs of hyperglycemia vs 48.3% (29/60) in the stan-
dard care group (Table VIII). There were no cases of intra-
cranial hypertension or tonsillar hypertrophy in either
group.
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Figure 2. Mean (SD) serum IGF-1 concentrations over time in infants in the standard neonatal care and rhIGF-1/rhIGFBP-3
groups (n = 121).
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Days from birth
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Overall: rhIGF-1/rhIGFBP-3, n = 60; standard neonatal care, n = 60
Days from birth
Figure 4. A, Average weight, B, length, and C, head circumference by treatment group (FAS).
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Table I. Verbatim terms reported in relation to common treatment-emergent AEs
AE/preferred term Verbatim terms
Patent ductus arteriosus “Persistent ductus arteriosus,” “patent ductus arteriosus that requires treatment,” “patent ductus arteriosus that need treatment,” “PDA,”
“large PDA,” “large patent ductus arteriosus,” “patent ductus arteriosus, moderately hemodynamically significant,” “patent ductus
arteriosus, minor hemodynamically significant,” “PDA of 3.4 mm detected on first ECHO,” “reopening of ductus arteriosus,” “reopening
of patent ductus arteriosus,” “big patent ductus arteriosus,” “small patent ductus arteriosus,” “patent ductus arteriosus,
hemodynamically significant,” “patent ductus arteriosa without any clinical significance,” “small PDA again,” “homonymic significant
patent ductus arteriosus,” “patent ductus arteriosus (PDA),” “small closing patent ductus arteriosus,” “patent ductus
arteriosus 2.1 mm,” “patent ductus arteriosus with shunt pulsating flow pattern,” “PDA prior to treatment,” “patent ductus arteriosus
from echocardiogram,” “PDA observed on echocardiogram”
Anemia neonatal “Anemia,” “anemi,” “anemia requiring transfusion,” “anaemia,” “anaemia of prematurity,” “anemie,” “tired, pale, listless due to anemia,”
“anaemia needed transfusion,” “neonatal anaemia,” “anemia of prematurity,” “symptomatic anemia”
Neonatal respiratory
distress syndrome
“Respiratory distress syndrome,” “RDS,” “respiratory distress,” “hyaline membrane disease,” “infant respiratory distress syndrome,”
“respiratory distress/hyaline membrane disease”
Jaundice neonatal “Jaundice,” “jaundiced,” “neonatal jaundice,” “icterus,” “jaundice requiring phototherapy,” “intermittent jaundice,” “jaundice requiring
treatment with phototherapy”
Infantile apneic attack “Apnéas,” “apneas,” “apnéa,” “apnea of prematurity,” “apnea,” “apnoea,” “prematurity apnea,” “apnoea crisis,” “recurrent apnea,”
“recurrent apnoeas,” “sudden and severe apnoea,” “severe apnoea,” “apnea episode,” “apnea neonatal,” “crisis of apnea”
Neonatal hypotension “Hypotension,” “low blood pressure,” “hypotension (low blood pressure),” “systemic hypotension,” “hypotensive (mean 21),” “intermittent
hypotension,” “hypotension (intermittent),” “hypotension, MAP 26”
Hyperglycemia “Hyperglycemia,” “hyperglycaemia,” “hyperglucemia,” “hyperglicemia,” “hyperglycemia (intermittent),” “hyperglycemia, blood
glucose 26 mmol, insulin infusion commenced,” “hyperglycemia, blood glucose 58 mmol stat dose of insulin given,” “hyperglycemia,
blood glucose 45 mmol, insulin infusion concentration and dose increased”
Neonatal hyponatremia “Hyponatremia,” “hyponatremi,” “low natrium,” “hyponatriemia,” “hyponatraemia,” “mild hyponatremia,” “severe hyponatremia”
Sepsis neonatal “Suspected sepsis, blood cultures negative,” “suspected septicemia,” “suspected sepsis,” “sepsis,” “sepsis (blood culture negative),”
“sepsis due to Enterococcus faecalis, Staphilococcus aureus, and Staphilococcus haemoliticus,” “late onset neonatal sepsis,” “late
onset sepsis,” “suspected sepsis not confirmed (CRP negative),” “suspected sepsis (blood culture and tracheal aspiration were
negative, the adverse event was not confirmed,” “suspected sepsis (clinical instability, elevation of CRP but blood and CSF cultures
were negative),” “clinical sepsis (desaturations, elevation of CRP but blood culture was negative),” “suspected sepsis (recurrent apneas
but blood culture and CRP were negative),” “suspected sepsis (blood culture was negative) for clinical instability (desaturations),”
“sepsis (etiology unknown, blood culture was negative),” “clinical sepsis (PCR, blood culture negative),” “possibility to sepsis, no
bacteria found in blood culture,” “presumed sepsis (blood cultures negative after 6 days),” “sepsis presumed, no growth on blood
culture or nasopharyngeal aspirate,” “presumed sepsis, blood cultures negative,” “sepsis of unknown etiology,” “suspected sepsis, not
confirmed,” “suspected sepsis, not confirmed, etiology unknown,” “neonatal septicemia, staphylococcus capitis grown from blood
culture,” “possible sepsis, cultures negative,” “suspected sepsis, rising infection parameters, no bacteria detected in cultures,” “early
onset sepsis,” “presumed long line sepsis, cultures negative,” suspected sepsis due to severe desaturations,” “suspected sepsis (CSF
and blood cultures were negative),” “clinical sepsis, etiology unknown (cultures remained negative),” “sepsis presumed in line with
routine neonatal care of extreme premature baby, antibiotics stopped when sepsis ruled out,” “sepsis suspected and therefore treated
with antibiotics but blood cultures negative after 6 days,” “sepsis suspected, blood cultures showed no growth after 6 days
incubation,” “sepsis (no growth from blood cultures after 6 days incubation, no other source of infection suspected),” “sepsis
suspected, no sepsis confirmed,” “suspected sepsis (in line with routine preterm neonatal care) (blood cultures negative after
6 days) antibiotics stopped,” “presumed sepsis, no confirmed on blood cultures,” “central line associated blood stream infection from
PICC line,” “clinical sepsis (bloody stool), and blood cultures negative”
Hypoglycemia neonatal “Hypoglycemia,” “asymptomatic hypoglycaemia,” “hypoglicemia,” “hypoglycaemia,” “hypoglycaemia as peripheral venous line delivering
TPN was leaking,” “hypoglycaemia (intermittent),” “hypoglycaemia, asymptomatic,” “hypoglycaemia, 1.8,” “hypoglycaemia, 1.6,”
“hypoglycaemia (1.0 mmol/l at 6 pm)”
Metabolic acidosis “Metabolic acidosis,” “metabolic acidosis on blood gas”
Staphylococcal sepsis “Septicemia: stafyloccus epidermidis,” “staphylococcus epidermis in the blood,” “coagulase negative staphylococci septicaemia,”
“sepsis (staphylococcus epidermidis),” “sepsis due to Bacillus Amyloliquefaciens and Staphilococcus Epidermidis,” “sepsis due to
staphylococcus epidermidis,” “sepsis by staphylococcus aureus,” “sepsis by oxacillin-resistant staphylococcus epidermis,” “sepsis by
Staphilococcus Aureus,” “sepsis by Staphilococcus epidermidis probably originated by a skin lesion,” “sepsis by staphylococcus
warneri,” “sepsis by MRSA,” “sepsis from staphylococcus capitis,” “sepsis from staphylococcus epidermidis,” “coagulase-negative
staphylococcal sepsis,” “positive blood culture-staphylococcus epidermidis,” “neonatal septicaemia, staphylococcus capitis grown
from blood culture,” “positive blood culture, staphylococcus epidermidis,” “mild sepsis (Staphylococcus epidermidis),” “septicemia
with coagulase negative staphylococci,” “sepsis staph aureus and KNS,” “staphylococcus sepsis,” “sepsis due to staphylococcus
epidermidis and staphylococcus warneri,” “sepsis from staphylococcus capitis and epidermidis,” “staphylococcus aureus bacteraemia
sepsis,” “sepsis by methicillin-resistant staphylococcus aureaus (MRSA),” “clinical sepsis by staphylococcus capitis oxacilline
resistant,” “sepsis staphylococcus haemolitycus,” “sepsis from Staphylococcus Haemolitycus,” “sepsis, blood cultures Staphyloccus
capitis positive,” “blood cultures showed mixed coagulase negative staphylococci,” “sepsis, confirmed coag neg staph from blood
cultures,” “sepsis suspected, confirmed Staphylococcis capitis,” “presumed sepsis, coagulase negative staph isolated from aerobic
bottle after 1 day incubation,” “sepsis, Staphylococcus pettenkoferi,” “sepsis confirmed, Staphylococcus aureus and Staphylococcus
epidermitis,” “positive blood culture staphylococci epidermidis,” “positive blood culture (gram positive cocci) Staphylococcus
Epidermidis,” “sepsis (positive blood culture Staphylococcus epidermidis noted),” “coagulase negative staphylococci septicaemia,”
“sepsis from staphylococcus epidermidis catheter associated”
Neonatal hypoxia “Increasing need of oxygen,” “oxygen saturation decreased,” “neonatal hypoxia,” “repeated desaturations,” “low saturation,” “poor
saturations and blood gases,” “desaturations,” “episodes of desaturations,” “desaturation crisis,” “frequent desaturations,” “persistent
need of oxygen in nCPAP with clinical instability (frequent desaturations),” “persistent need of oxygen in CPAP,” “persistent need of
oxygen,” “prolonged need of oxygen,” “hypoxia,” “desaturation, need of increased oxygen,” “increased need of oxygen,” “oxygen
saturation dips,” “necessity of nCPAP at 28 days of life without oxygen,” “oxygenation problems due to PIE,” “respiratory step
up (increase in the oxygen requirement),” “profound desaturation after a feed,” “desaturation following a feed,” “poor oxygen
saturation,” “oxygen desaturations,” “desaturation associated with feeding,” “low oxygen saturation (14%)”
(continued)
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Table I. Continued
AE/preferred term Verbatim terms
Neonatal respiratory
failure
“Respiratory insufficiency,” “respiratory crisis,” “pulmonary insufficiency,” “respiratory failure, ventilator dependent,” “respiratory failure
unable to ventilate,” “reintubation for impending respiratory failure,” “respiratory instability,” “respiratory failure unable to ventilate
infant,” “respiratory failure”
Hypokalemia “Hypokalemia,” “ipokaliemia,” “hypokalaemia,” “hypokalemi,” “hypopotassemia”
Bradycardia neonatal “Bradycardia,” “bradycardia episodes,” “bradycardia (mean heart rate 56.3 bpm),” “bradycardia (heart rate <60 bpm)”
Hyperbilirubinemia
neonatal
“Hyperbilirubinemia,” “hyperbilirubinemi,” “hyperbillirubin,” “hyperbillirubinemi,” “hyperbilirubinaemia,” “conjugated hyperbilirubaemia”
Pulmonary hypertension “Persistent pulmonary hypertension,” “pulmonary hypertension,” “Persistent pulmonary hypertension of the newborn,” “severe pulmonary
hypertension on study echocardiogram”
CPAP, continuous positive airway pressure; CRP, C-reactive protein; CSF, cerebrospinal fluid; MRSA, methicillin-resistant Staphylococcus aureus; nCPAP, nasal continuous positive airway pres-
sure; PICC, peripherally inserted central catheter; PIE, pulmonary interstitial emphysema.
Table II. Anticipated distribution of the maximum se-
verity of ROP (standard care and rhIGF-1/ rhIGFBP-3
groups) used for calculation of sample size*
ROP 0 1 2 3 >3 Total
Standard care (%) 26 15 24 18 17 100
rhIGF-1/rhIGFBP-3 (%) 49 19 19 9 4 100
*Standard care group distribution based on registry data (Austeng. Arch Ophthalmol.
2009;127:1315-9); estimated treatment effect in the rhIGF-1/rhIGFBP-3 group based on the
following assumptions: For each outcome of the maximum severity of ROP stage, it is assumed
that 25% of the children will not benefit from the treatment, 25% will have their maximum
severity of ROP stage reduced by 1 level (eg, from 2 to 1), and 50% will have their maximum
severity of ROP stage reduced 2 levels (eg, from 3+ to 2).















Mean 23.8 27.4 18.9
Range 0.1-45.3 0.1-45.3 1.8-26.7
Ratio of duration of
exposure to expected
duration, d†
Mean 0.86 0.85 0.88
Range 0.0-1.0 0.0-1.0 0.6-1.0
Overall dose, µg/kg‡
Mean 5907.5 6849.8 4639.0
Range 16.0-11,321.9 16.0-11,321.9 460.9-6664.1
Average daily dose,
µg/kg/24 hours§
Mean 248.1 250.0 245.4
Range 131.1-250.0 250.0-250.0 131.1-250.0
Interruptions, no.
Mean 4.0 5.7 1.6
Range 0-83 0-83 0-9
Length interruptions, h
Mean 7.5 10.2 3.9
Range 0.0-52.6 0.0-52.6 0.0-30.8
*Total duration of exposure defined as (study medication end date – study medication start
date) – duration of interruptions.
†Ratio of duration of exposure to expected duration defined as total duration of exposure / (29
weeks × 7 + 6 days) or the last day in the study–(birth weeks × 7 + day) + 1.
‡Total dose (µg/kg) defined as the sum of weight-adjusted doses during the exposure.
§Average daily dose (µg/kg/24 hours) defined as overall dose/total duration of exposure across
the entire study.
Table VI. Maximum severity of ROP stage across all ex-
aminations by a central pediatric ophthalmologist by ges-











Infants with ROP examination, no. 26 25 9
Infants with maximum severity
of ROP of stage, no. (%)
0 8 (30.8) 5 (20.0) 2 (22.2)
1 2 (7.7) 2 (8.0) 0
2 9 (34.6) 7 (28.0) 4 (44.4)
3 2 (7.7) 5 (20.0) 1 (11.1)
3+ 5 (19.2) 6 (24.0) 2 (22.2)
4 0 0 0
5 0 0 0
≥3 7 (26.9) 11 (44.0) 3 (33.3)
Missing 6 10 1
≥26 wk n = 28 n = 26 n = 14
Infants with ROP examination, no. 24 22 13
Infants with maximum severity
of ROP of stage, no. (%)
0 16 (66.7) 9 (40.9) 6 (46.2)
1 2 (8.3) 2 (9.1) 2 (15.4)
2 4 (16.7) 10 (45.5) 4 (30.8)
3 1 (4.2) 1 (4.5) 1 (7.7)
3+ 1 (4.2) 0 0
4 0 0 0
5 0 0 0
≥3 2 (8.3) 1 (4.5) 1 (7.7)
Missing 4 4 1
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FAS (n = 35) ES (n = 10)
<26 wk
Infants with BPD assessment, no. 25 25 8
Severity of BPD, no. (%)
No BPD 1 (4.0) 1 (4.0) 0
Mild 5 (20.0) 10 (40.0) 4 (50.0)
Moderate 4 (16.0) 7 (28.0) 3 (37.5)
Severe 14 (56.0) 6 (24.0) 1 (12.5)
Unable to determine 1 (4.0) 1 (4.0) 0
≥26 wk
n 28 26 14
Infants with BPD assessment, no. 24 22 13
Severity of BPD, no. (%)
No BPD 3 (12.5) 3 (13.6) 2 (15.4)
Mild 11 (45.8) 13 (59.1) 9 (69.2)
Moderate 1 (4.2) 2 (9.1) 2 (15.4)
Severe 8 (33.3) 4 (18.2) 0
Unable to determine 1 (4.2) 0 0
Table VIII. Percentage of infants with IVH by grade and






FAS (n = 35) ES (n = 10)
<26 wk
IVH grade, no. (%)
0-1 20 (62.5) 27 (77.1) 9 (90.0)
2 3 (9.4) 3 (8.6) 1 (10.0)
3 6 (18.8) 3 (8.6) 0
4 3 (9.4) 2 (5.7) 0
≥26 wk
n 28 26 14
IVH grade, no. (%)
0-1 22 (78.6) 22 (84.6) 11 (78.6)
2 1 (3.6) 1 (3.8) 1 (7.1)
3 3 (10.7) 3 (11.5) 2 (14.3)
4 2 (7.1) 0 0
Table IX. Post hoc analysis of BPD including all-cause









Severity of BPD No. (%) 95% CI No. (%) 95% CI
No BPD/mild 20 (35.7) (24.5-48.8) 27 (45.8) (33.7-58.3)
Moderate 5 (8.9) (3.9-19.3) 9 (15.3) (8.2-26.5)
Severe/death 29 (51.8) (39.0-64.3) 22 (37.3) (26.1-50.1)
Unable to determine 2 (3.6) (1.0-12.1) 1 (1.7) (0.3-9.0)
*There were 19 all-cause deaths that occurred during the study, 12 deaths in the rhIGF-1/
rhIGFBP-3 group and 7 deaths in the standard care group.
†Four infants in the standard care group and 2 infants in the rhIGF-1/rhIGFBP-3 FAS were with-
drawn from the study before being assessed for BPD.
Table X. Most common treatment-emergent AEs (pre-














Patent ductus arteriosus 51 (85.0) 71 55 (90.2) 80
Anemia neonatal 44 (73.3) 157 46 (75.4) 210
Neonatal respiratory
distress syndrome
34 (56.7) 49 29 (47.5) 34
Jaundice neonatal 30 (50.0) 38 28 (45.9) 34
Infantile apneic attack 17 (28.3) 35 27 (44.3) 48
Neonatal hypotension 18 (30.0) 30 25 (41.0) 35
Hyperglycemia 29 (48.3) 58 24 (39.3) 41
Neonatal hyponatremia 22 (36.7) 39 23 (37.7) 43
Sepsis neonatal* 15 (25.0) 30 23 (37.7) 41
Hypoglycemia neonatal 19 (31.7) 28 18 (29.5) 22
Metabolic acidosis 22 (36.7) 46 17 (27.9) 48
Staphylococcal sepsis 19 (31.7) 25 16 (26.2) 24
Neonatal hypoxia† 13 (21.7) 22 14 (23.0) 17
Neonatal respiratory failure‡ 14 (23.3) 18 14 (23.0) 22
Hypokalemia 11 (18.3) 18 14 (23.0) 24
Bradycardia neonatal§ 5 (8.3) 6 13 (21.3) 19
Hyperbilirubinemia neonatal 14 (23.3) 18 12 (19.7) 14
Pulmonary hypertension 12 (20.0) 14 8 (13.1) 8
Events of ROP, BPD, and IVH also were reported as treatment-emergent AEs in some but not
all cases; however, they are not included in the table because these are efficacy outcomes.
*Verbatim terms include suspected/presumed sepsis and some microbiologically confirmed cases
of sepsis, but do not encompass all cases of sepsis (nonspecific term). See Table I for a list of
reported verbatim terms under the preferred term “sepsis neonatal.”
†See Table I for verbatim terms reported under the preferred term “neonatal hypoxia.”
‡See Table I for verbatim terms reported under the preferred term “neonatal respiratory failure.”
§Frequency in rhIGF-1/rhIGFBP-3 group at least twice that of the standard care group.
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